The Emerging, Multifaceted Role of WTAP in Cancer and Cancer Therapeutics

Abstract

Cancer is a grave and persistent illness, with the rates of both its occurrence and death toll increasing at an alarming pace. N6-methyladenosine (m6A), the most prevalent mRNA modification in eukaryotic organisms, is catalyzed by methyltransferases and has a significant impact on various aspects of cancer progression. WT1-associated protein (WTAP) is a crucial component of the m6A methyltransferase complex, catalyzing m6A methylation on RNA. It has been demonstrated to participate in numerous cellular pathophysiological processes, including X chromosome inactivation, cell proliferation, cell cycle regulation, and alternative splicing. A better understanding of the role of WTAP in cancer may render it a reliable factor for early diagnosis and prognosis, as well as a key therapeutic target for cancer treatment. It has been found that WTAP is closely related to tumor cell cycle regulation, metabolic regulation, autophagy, tumor immunity, ferroptosis, epithelial mesenchymal transformation (EMT), and drug resistance. In this review, we will focus on the latest advances in the biological functions of WTAP in cancer, and explore the prospects of its application in clinical diagnosis and therapy.

Application of New Molecular Probes in the Diagnosis and Treatment of Malignant Tumors

“…In a recent study conducted by Cao et al, a pioneering transformer-based end-to-end deep learning model, MVI-TR, was introduced as substantial preoperative predictive utility for early-stage hepatocellular carcinoma patients [10]. Furthermore, an examination of recent research elucidating the involvement of WT1-associated protein (WTAP) in oncogenesis and its potential therapeutic implications was undertaken [11]. Another article reviews the current epidemiology and mechanisms of cardiac toxicity in pan-cancer therapies, stressing the importance of assessing relevant risk factors [12].…”